Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT06393374 trial: what clinicians have said so far
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- NCT06393374 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT06393374 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06393374 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 post on Bluesky, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Pembrolizumab; Sacituzumab tirumotecan; Capecitabine
- Arms
- Pembrolizumab + sacituzumab tirumotecan · Experimental
- Treatment of Physician's Choice · Active comparator
- Enrollment
- 1,530 (estimated)
- Primary outcomes
- Invasive Disease-Free Survival (iDFS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jun 24, 2024
- Primary completion
- Dec 16, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06393374 · updated Nov 18, 2026